Recombinant Human TGF‑ beta 1 (Catalog # 240-B) inhibits Recombinant Mouse IL‑4 (Catalog # 404-ML) induced proliferation in the HT‑2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of ...read more
Chinese hamster ovary cell line CHO-derived recombinant human TGF-beta 1 (R&D Systems, Catalog # 240-B)Ala279-Ser390Accession # P01137
Detects TGF‑ beta 1/1.2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 10% cross-reactivity with recombinant amphibian TGF‑ beta 5 is observed and less than 2% cross-reactivity with recombinant human TGF‑ beta 3, recombinant chicken TGF‑ beta 3, and porcine TGF‑ beta 2 is observed.
Ion exchange-purified from egg yolks
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for TGF-beta 1/1.2 Antibody [Unconjugated]
TGF-beta 1 (transforming growth factor beta 1) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cystine knot structure. TGF-beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition. Each TGF-beta isoform has some non-redundant functions; for TGF-beta 1, mice with targeted deletion show defects in hematopoiesis and endothelial differentiation, and die of overwhelming inflammation. Human TGF-beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein. A furin-like convertase processes the proprotein to generate an N-terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF- beta 1. Disulfide-linked homodimers of LAP and TGF-beta 1 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex. Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix. TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins. Mature human TGF-beta 1 shares 100% aa identity with pig, dog and cow TGF-beta 1, and 99% aa identity with mouse, rat and horse TGF-beta 1. It demonstrates cross-species activity. TGF-beta 1 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK‑1. This complex phosphorylates and activates Smad proteins that regulate transcription. Contributions of the accessory receptors betaglycan (also known as TGF-beta RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-beta in different contexts.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Publications for TGF-beta 1/1.2 Antibody (AB-101-NA)(1)
We have publications tested in 1 confirmed species: Human.